Doxycycline hyclate
- CAS No.
- 24390-14-5
- Chemical Name:
- Doxycycline hyclate
- Synonyms
- DOXYCYCLINE HYDRATE;Doxycycline hyclate CRS;Doxycycline Hydrochlocide;Doxycycline Hyclate Soluble Powder;Doxycycline for system suitability CRS;WC2031;DoxycycL;ine hycL;Doxycycline Hc1;Doxycycline API
- CBNumber:
- CB6136567
- Molecular Formula:
- C24H31ClN2O9
- Molecular Weight:
- 526.97
- MDL Number:
- MFCD06200253
- MOL File:
- 24390-14-5.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Melting point | 206-209C (dec.) |
|---|---|
| alpha | D25 -110° (c = 1 in 0.01N methanolic HCl) |
| RTECS | QI8925000 |
| storage temp. | 2-8°C |
| solubility | H2O: soluble50mg/mL |
| form | Yellow to yellow-green crystalline solid |
| color | yellow to greenish-yellow |
| biological source | synthetic |
| Water Solubility | Soluble in water to 50mg/ml. May require warming.Soluble in water, methanol. Sparingly soluble in ethanol. Insoluble in chloroform and ether. |
| Merck | 14,3440 |
| BRN | 5702728 |
| Major Application | clinical testing |
| InChIKey | HALQELOKLVRWRI-VDBOFHIQSA-N |
| SMILES | C(O)C.O[C@@]12C(C(C(=O)N)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]([C@]1([H])[C@H](C3C=CC=C(O)C=3C(=O)C1=C2O)C)O)=O.Cl |&1:4,12,16,18,19,21,r| |
| NCI Dictionary of Cancer Terms | doxycycline hyclate |
| FDA UNII | 19XTS3T51U |
| Proposition 65 List | Doxycycline Hyclate (internal use) |
| UNSPSC Code | 51284027 |
| NACRES | NA.85 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |    GHS07,GHS08,GHS09 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H315-H319-H335-H361fd-H410 | |||||||||
| Precautionary statements | P202-P261-P273-P302+P352-P305+P351+P338-P308+P313 | |||||||||
| target organs | Respiratory system | |||||||||
| PPE | dust mask type N95 (US), Eyeshields, Gloves | |||||||||
| Hazard Codes | Xn | |||||||||
| Risk Statements | 22-36/37/38 | |||||||||
| Safety Statements | 26 | |||||||||
| WGK Germany | 3 | |||||||||
| HS Code | 29413000 | |||||||||
| Storage Class | 11 - Combustible Solids | |||||||||
| Hazard Classifications | Acute Tox. 4 Oral Aquatic Chronic 3 Eye Irrit. 2 Repr. 2 Skin Irrit. 2 STOT SE 3 |
|||||||||
| Toxicity | LD50 i.p. in rats: 262 mg/kg (Goldenthal) | |||||||||
| NFPA 704 |
|
Doxycycline hyclate price More Price(89)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | Y0001714 | Doxycycline for system suitability European Pharmacopoeia (EP) Reference Standard | 24390-14-5 | 10 mg | $254 | 2026-04-30 | Buy |
| Sigma-Aldrich | D5207 | Doxycycline hyclate Suitable for Cell Culture | 24390-14-5 | 1 g | $70.6 | 2026-04-30 | Buy |
| Sigma-Aldrich | D5207 | Doxycycline hyclate Suitable for Cell Culture | 24390-14-5 | 5 g | $183 | 2026-04-30 | Buy |
| Sigma-Aldrich | D5207 | Doxycycline hyclate Suitable for Cell Culture | 24390-14-5 | 10 g | $290 | 2026-04-30 | Buy |
| Sigma-Aldrich | D3000000 | Doxycycline hyclate European Pharmacopoeia (EP) Reference Standard | 24390-14-5 | 50 mg | $254 | 2026-04-30 | Buy |
Doxycycline hyclate Chemical Properties,Uses,Production
Description
Doxycycline Hyclate is the hyclate salt form of doxycycline, is a broad-spectrum tetracycline antibiotic. It inhibits bacterial protein synthesis by binding to ribosomes. Doxycycline also selectively inhibits human matrix metalloproteinase-8 (MMP-8) and MMP-13 over MMP-1 with 50, 60, and 5% inhibition, respectively, when used at a concentration of 30 μM. It can be used as a regulator for inducible gene expression systems where expression depends on either the presence (Tet-On) or absence (Tet-Off) of doxycycline. Formulations containing doxycycline have been used in the treatment of bacterial infections and the prevention of malaria.
Chemical Properties
Doxycycline hyclate is a yellow, hygroscopic crystalline powder, freely soluble in water and in methanol, sparingly soluble in ethanol (96 per cent), it dissolves in solutions of alkali hydroxides and carbonates.
Uses
Doxycycline hyclate is a member of the tetracycline antibiotics group, and is commonly used to treat a variety of infections. It is used in the treatment of chlamydia, rickettsia, mycoplasma and some spirochete infections. It is also used to inhibit matrix metalloproteinases at subantimicrobial doses. Inhibits matrix metalloproteinases at subantimicrobial doses.
Definition
ChEBI: The hemiethanolate hemihydrate of doxycycline hydrochloride. A semi-synthetic tetracycline antibiotic, it is used to inhibit bacterial protein synthesis and treat non-gonococcal urethritis and cervicitis, exacerbations of bronchitis in patients with chroni obstructive pulmonary disease (COPD), and adult periodontitis.
Application
Doxycycline hyclate is a synthetic oxytetracycline derivative with similar antimicrobial activity. It has been used to eliminate Borrelia burgdorferi and Anaplasma phagocytophilum in rodent reservoirs and to eliminate Ixodes scapularis ticks. It is a broad spectrum inhibitor used to inhibit matrix metalloproteinases(MMP), such as type 1 collagenase in studies on wound healing and tissue remodeling. Doxycycline hyclate has also been used for the induction of glioma cells and human embryonic kidney 293T cells (HEK293T).
brand name
Atridox (QLT); Doryx (Faulding); Doryx (Warner Chilcott); Doxy (Abraxis); Doxychel Hyclate (Rachelle); Periostat (CollaGenex); Vibramycin (Pfizer);Abadox;Bassado;Bio-tab;Clisemina;Cloran;Cyclidox;Diocimex;Docostyl;Dosil;Dotur;Doxatet;Doxi sergo;Doxicento;Doxifin;Doxilen;Doximycin;Doxiten bio;Doxivis;Doxy-100;Doxy-basan;Doxybiocin;Doxycyl;Doxy-diolan;Doxydyn;Doxyfim;Doxygram;Doxylag;Doxylan;Doxylar;Doxylets;Doxymycin;Doxy-p;Doxytem;Doxy-wolff;Dumoxin;Duradoxal;Esadoxi;Farmodoxi;Ghimadox;Gram-val;Granudoxy;Helvedoclyn;Icladox;Miraclin;Monocline;Monodoxin;Novelciclina;Philcociclina;Roxyne;Semelciclina;Sigadoxin;Solupen;Stamicina;Supracyclin;Tetrasan;Unacil;Vibracina;Vibramicina;Vibramycin hyclate;Vibraveineuse;Vibravenosa;Ximicina;Zadorin.
World Health Organization (WHO)
Doxycycline, a semi-synthetic tetracycline derivative, was first introduced into medicine in 1960 for the treatment of bacterial, rickettsial and amoebic infections. Although allergic manifestations are uncommon, injectable preparations have occasionally resulted in severe anaphylactoid reactions. Clinical features and the fact that asthmatic patients seemed to be particularly at risk lead to suspect a sulfite preservative in the formulation more than doxycycline itself. Rapid administration may also be a factor. Injectable preparations of doxycycline hyclate are included in the WHO Model List of Essential Drugs.
General Description
Doxycycline hyclate belongs to the second generation of tetracycline antibiotics family. Doxycycline hyclate shows minimal side effects upon usage. It is effective for the treatment of recurrent aphthous stomatitis (RAS) and promotes speedy recovery.
Biochem/physiol Actions
Doxycycline hyclate inhibits the inflammatory response to the Lyme Disease Spirochete Borrelia burgdorferi. It is a broad spectrum inhibitor of matrix metalloproteinases in vivo.
storage
+4°C
Mode of action
Tetracycline antimicrobials bind to the bacterial 30S ribosomal subunit interfering with tRNA/mRNA interaction, ultimately inhibiting protein synthesis. Tetracyclines can inhibit the MMP enzyme family and inhibit mitochondrial biogenesis.
References
[1] WILLIAMSON G M. The in vitro activity of Vibramycin (Doxycycline).[J]. Chemotherapia, 1968, 13: Suppl:1-20. DOI: 10.1159/000220576
[2] MICHAEL O. GRIFFIN Francisco J V Guillermo Ceballos. Tetracycline compounds with non-antimicrobial organ protective properties: Possible mechanisms of action[J]. Pharmacological research, 2011, 63 2: Pages 102-107. DOI: 10.1016/j.phrs.2010.10.004
[3] CHOPRA I. Tetracycline analogs whose primary target is not the bacterial ribosome.[J]. Antimicrobial Agents and Chemotherapy, 1994, 38 4: 637-640. DOI: 10.1128/aac.38.4.637
[4] GERALD N. SMITH JR. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: Relationship to structure of the enzyme[J]. Arthritis & Rheumatology, 2001, 42 6: 1140-1146. DOI: 10.1002/1529-0131(199906)42:6<1140::aid-anr10>3.0.co;2-7
[5] D J GOULD. A novel doxycycline inducible autoregulatory plasmid which displays ‘on’/‘off’ regulation suited to gene therapy applications[J]. Gene Therapy, 2001, 7 24: 2061-2070. DOI: 10.1038/sj.gt.3301354
[6] ZHIJIE LI. Simple piggyBac transposon-based mammalian cell expression system for inducible protein production.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2013: 5004-5009. DOI: 10.1073/pnas.1218620110
Doxycycline hyclate Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Henan Qiande Pharmaceutical Co. LTD | 19103869591 | 1814581@qq.com | China | 213 | 58 |
| Hubei Wanye Zhongcheng Chemical Reagent Co., Ltd. | 18671296875 | 1205035102@qq.com | China | 4300 | 58 |
| Wuhan DingCheng Biochemical Co.Ltd | 81302558 13545255233 | 2851686513@qq.com | China | 745 | 58 |
| Suzhou Yuanhuan Pharmaceutical Technology Co., Ltd. | 0512-18136053398 18136053398 | 2982784935@qq.com | China | 80 | 58 |
| Hubei Yangyi Xinsheng Biological Medicine Co., LTD | 15927387803 15927387803 | 2263659332@qq.com | China | 168 | 58 |
| J & K SCIENTIFIC LTD. | 18210857532 18210857532 | jkinfo@jkchemical.com | China | 96815 | 76 |
| 3B Pharmachem (Wuhan) International Co.,Ltd. | 18930552037 | 3bsc@sina.com | China | 15813 | 69 |
| TCI (Shanghai) Development Co., Ltd. | 021-67121386 | Sales-CN@TCIchemicals.com | China | 24512 | 81 |
| Energy Chemical | 400-0056266 | sales8178@energy-chemical.com | China | 44850 | 61 |
| Beijing Ouhe Technology Co., Ltd | 13552068683 13522913783 | 2355560935@qq.com | China | 11777 | 60 |
Related articles
- Unveiling Doxycycline Hyclate: An In-Depth Analysis
- Doxycycline hyclate, a widely recognized and utilized antibiotic, plays a crucial role in the medical and chemical fields.
- Oct 22,2024
View Lastest Price from Doxycycline hyclate manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-09-12 | Doxycycline hyclate
24390-14-5
|
0.99 | RongNa Biotechnology Co.,Ltd | ||||
 |
2026-09-11 | Doxycycline Hyclate
24390-14-5
|
1g | More Than 99% | 100kg/Month | BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | ||
 |
2026-09-11 | Doxycycline hyclate
24390-14-5
|
25KG | 88.0%~94.0%;CP2015 | 8000kg/month | WUHAN FORTUNA CHEMICAL CO., LTD |
-
- Doxycycline hyclate
24390-14-5
- 0.99
- RongNa Biotechnology Co.,Ltd
-
- Doxycycline Hyclate
24390-14-5
- $0.00
- More Than 99%
- BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
-
- Doxycycline hyclate
24390-14-5
- 88.0%~94.0%;CP2015
- WUHAN FORTUNA CHEMICAL CO., LTD
24390-14-5(Doxycycline hyclate)Related Search:
1of4
